4/2
08:31 am
ostx
OS Therapies Inc (NYSE: OSTX) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $19.00 price target on the stock.
Medium
Report
OS Therapies Inc (NYSE: OSTX) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $19.00 price target on the stock.
4/2
08:06 am
ostx
OS Therapies to Host Analyst Day at NYSE on April 7, 2025 [Yahoo! Finance]
Low
Report
OS Therapies to Host Analyst Day at NYSE on April 7, 2025 [Yahoo! Finance]
4/2
07:40 am
ostx
OS Therapies to Host Analyst Day at NYSE on April 7, 2025
High
Report
OS Therapies to Host Analyst Day at NYSE on April 7, 2025
3/31
04:40 pm
ostx
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/31
04:30 pm
ostx
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
High
Report
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
3/31
08:35 am
ostx
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
Neutral
Report
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
3/31
07:40 am
ostx
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
Low
Report
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
3/25
07:40 am
ostx
OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Medium
Report
OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
3/23
08:58 am
ostx
OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
Neutral
Report
OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
3/21
07:40 am
ostx
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
High
Report
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
3/13
08:01 am
ostx
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference [Yahoo! Finance]
Medium
Report
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference [Yahoo! Finance]
3/13
07:40 am
ostx
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
High
Report
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
3/11
07:40 am
ostx
OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
Neutral
Report
OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
2/26
04:01 pm
ostx
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
Low
Report
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
2/24
07:25 am
ostx
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Low
Report
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
2/20
08:00 am
ostx
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
Medium
Report
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
2/20
05:20 am
ostx
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2 [Yahoo! Finance]
Medium
Report
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2 [Yahoo! Finance]
2/20
05:00 am
ostx
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Medium
Report
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
2/14
08:01 am
ostx
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing [Yahoo! Finance]
High
Report
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing [Yahoo! Finance]
2/14
07:36 am
ostx
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
High
Report
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
2/4
07:33 am
ostx
OS Therapies Provides Corporate Update
High
Report
OS Therapies Provides Corporate Update
1/30
09:22 am
ostx
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
High
Report
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
1/29
09:22 am
ostx
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
Medium
Report
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
1/16
02:04 pm
ostx
OS Therapies Inc (NYSE: OSTX) had its price target raised by analysts at Maxim Group from $8.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
OS Therapies Inc (NYSE: OSTX) had its price target raised by analysts at Maxim Group from $8.00 to $15.00. They now have a "buy" rating on the stock.
1/15
11:22 am
ostx
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
Medium
Report
OS Therapies Inc (NYSE: OSTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.